Parallel Advisors’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-8
| Closed | – | – | 3744 |
|
|
2025
Q1 | $0 | Hold |
8
| – | – | ﹤0.01% | 3720 |
|
|
2024
Q4 | $1 | Hold |
8
| – | – | ﹤0.01% | 3517 |
|
|
2024
Q3 | $2 | Hold |
8
| – | – | ﹤0.01% | 3393 |
|
|
2024
Q2 | $4 | Hold |
8
| – | – | ﹤0.01% | 3302 |
|
|
2024
Q1 | $8 | Hold |
8
| – | – | ﹤0.01% | 3277 |
|
|
2023
Q4 | $5 | Hold |
8
| – | – | ﹤0.01% | 3296 |
|
|
2023
Q3 | $8 | Hold |
8
| – | – | ﹤0.01% | 3341 |
|
|
2023
Q2 | $11 | Hold |
8
| – | – | ﹤0.01% | 3342 |
|
|
2023
Q1 | $13 | Hold |
8
| – | – | ﹤0.01% | 3402 |
|
|
2022
Q4 | $12 | Hold |
8
| – | – | ﹤0.01% | 3327 |
|
|
2022
Q3 | $0 | Hold |
8
| – | – | ﹤0.01% | 3561 |
|
|
2022
Q2 | $0 | Hold |
8
| – | – | ﹤0.01% | 3423 |
|
|
2022
Q1 | $0 | Hold |
8
| – | – | ﹤0.01% | 3329 |
|
|
2021
Q4 | $0 | Hold |
8
| – | – | ﹤0.01% | 3333 |
|
|
2021
Q3 | $0 | Hold |
8
| – | – | ﹤0.01% | 3306 |
|
|
2021
Q2 | $0 | Hold |
8
| – | – | ﹤0.01% | 3094 |
|
|
2021
Q1 | $0 | Sell |
8
-1
| -11% | -$10 | ﹤0.01% | 2923 |
|
|
2020
Q4 | $0 | Hold |
9
| – | – | ﹤0.01% | 2757 |
|
|
2020
Q3 | $0 | Hold |
9
| – | – | ﹤0.01% | 2710 |
|
|
2020
Q2 | $0 | Hold |
9
| – | – | ﹤0.01% | 2762 |
|
|
2020
Q1 | $0 | Hold |
9
| – | – | ﹤0.01% | 2702 |
|
|
2019
Q4 | $0 | Sell |
9
-1
| -10% | -$17 | ﹤0.01% | 2518 |
|
|
2019
Q3 | $0 | Buy |
10
+9
| +900% | +$260 | ﹤0.01% | 2520 |
|
|
2019
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2464 |
|
|
2019
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2418 |
|
|
2018
Q4 | $0 | Buy |
+1
| New | +$41 | ﹤0.01% | 2323 |
|
Parallel Advisors's VIRX Position: Q2 2025 in Review
Parallel Advisors sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 8 shares.
Parallel Advisors first reported a position in VIRX in Q4 2018 and held it in 26 quarters. The position peaked at $13 in Q1 2023. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.
- Parallel Advisors reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- Parallel Advisors sold 8 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025.
- Parallel Advisors first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 26 quarters.
- Parallel Advisors's Viracta Therapeutics, Inc. Common Stock position peaked at $13 in Q1 2023.
- 0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.
Based on Parallel Advisors's 13F filing for Q2 2025, filed 8 Jul 2025.